KR960704900A - 시그마 및/또는 5에이취티1에이 (5ht1a) 수용기에 대한 활성을 가진 테트라히드로피리딘-(또는 4-히드록시피레리딘) 알킬아졸 (tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors) - Google Patents
시그마 및/또는 5에이취티1에이 (5ht1a) 수용기에 대한 활성을 가진 테트라히드로피리딘-(또는 4-히드록시피레리딘) 알킬아졸 (tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors) Download PDFInfo
- Publication number
- KR960704900A KR960704900A KR1019960701606A KR19960701606A KR960704900A KR 960704900 A KR960704900 A KR 960704900A KR 1019960701606 A KR1019960701606 A KR 1019960701606A KR 19960701606 A KR19960701606 A KR 19960701606A KR 960704900 A KR960704900 A KR 960704900A
- Authority
- KR
- South Korea
- Prior art keywords
- butyl
- tetrahydropyridinyl
- phenyl
- hydroxy
- piperidinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
본 발명은 불안증, 정신병, 간질, 경련, 운동기능 장애, 건망증, 뇌혈관 질환 또는 노인성 치매의 치료에 사용되는 약제로서 하기 일반식(I)의 화합물을 제공한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (5)
- 하기 일반식(I)의 화합물 및 그 생리적 허용염;상기 식에서, R1, R2및 R3은 동일하거나 상이하며, 각각 수소 원자, 할로겐 원자, 선형 또는 분지형 알킬라디칼, 퍼플루오로알킬 라디칼, 아릴 또는 치환된 아릴 라디칼 또는 알콕시 라디칼을 의미하며, 또한, 두 개의 인접한 라디칼은 방향족 또는 포화 고리를 이룰 수 있으며, A는 탄소 원자를 의미하고 점선은 추가의 결합을 의미하거나, 아니면 A는 히드록실기에 연결된 탄소 원자(C-OH)를 의미하고 점선은 추가의 결합이 없음을 의미하고, n은 2내지 6의 번위의 값이며, 4가 바람직하고, Z1는질소 원자 또는 C-R4로나타낼 수 있는치환된 탄소 원자를 의미하고, Z2는 질소 원자 또는 C-R5로 나타낼 수 있는 치환된 탄소 원자를 의미하고 Z4는 질소 원자 또는 C-R7로 나타낼 수 있는 치환된 탄소 원자를 의미하고, R4, R5, R6및 R7은 동일하거나 상이하며, 각각 수소 원자, 할로겐 원자, 선형 또는 분지형 알킬 라디칼, 히드록시 라디칼, 알콕시 라디칼, 카르복실 라디칼, 카르복스아미드 라디칼, 알킬 카르복실레이트 라디칼 또는 아릴 또는 치환된 아릴 라디칼을 의미하거나, 아니면 두 개의 인접한 라디칼이 방향족 고리일 수도 있고 아닐 수도 있는 또다른 고리의 일부를 이룰 수 있다.
- 제1항에 있어서, 하기군에서 선택되는 일반식(I)의 화합물; 1,4-클로로-1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-피라졸, 2. 4,5-클로로-1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-2-메틸-1H-이미다졸, 3. 1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-벤즈이미다졸, 4. 1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-1,2,4-트리아졸, 5. 4-클로로-1-〔4-(4-클로로페닐)-4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-피라졸 , 6. 4,5-디클로로-1-〔4-(4-히드록시-4-(4-클로로페닐-1-피페리디닐)부틸〕-2-메틸-1H-이미다졸, 7. 4-클로로-1-〔4-(4-히드록시-4-(3-트리플루오로메틸페닐)-1-피페리디닐)부틸〕-1H-피라졸, 8. 4,5-디클로로-1-〔4-(4-히드록시-4-(3-트리프루오로메틸페닐)-1-피페리디닐)부틸〕-2-메틸-1H-이미다졸, 9. 4,5-디클로로-1-〔4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐〕부틸〕-2-메틸-1H-이미다졸, 10. 1-〔4-〔4-(4-히드록시-4-페닐-1-피페리디닐〕부틸〕인돌, 11. 4,5-디클로로-1-{4-〔4-히드록시-4-(4-메틸페닐)-1-피페리디닐)부틸〕-2-메메틸-1A-이미다졸틸-1H-피라졸, 12. 1-〔4-(4-히드록시-4-페닐)-1-피페리디닐〕부틸}-1H-피라졸, 13. 1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-인다졸, 14. 2-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-인다졸, 15. 4-클로로-1-{4-〔4-(4-히드록시-4-(4-메틸페닐)-1-피페리디닐)부틸〕-1H-피라졸, 16. 4-클로로-1-〔4-(4-히드록시-4-(40메톡시페닐-1-피페리디닐)부틸〕-1H-피라졸, 17. 1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-2-페닐-1H-이미다졸, 18. 1-〔4-(4-히드록시-4-(4-메틸페닐)-1-피페리디닐)부틸〕-1H-벤즈이미다졸, 19. 4,5-디페닐-1-〔4-(4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-이미다졸, 20. 4-클로로-1-{4-〔4-히드록시-4-(1-나프틸)-1-피페리디닐〕부틸}-1H-피라졸, 21. 4-클로로-1-{4-〔4-히드록시-4-(2-나프틸)-1-피페리디닐)부틸〕-1H-피라졸, 22. 4-클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 23. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸, 24. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-1,2,4-트리아졸, 25. 4-클로로-1-{4-〔4-(4-클로로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 26. 4,5-디클로로-1-{4-〔4-(4-클로로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸, 27. 4-클로로-1-{4-〔4-(3-트리플루오로메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 28. 4,5-디클로로-2-메틸-1-{4-〔4-(3-트리플루오로메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-이니다졸, 29. 4-클로로-1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 30. 4,5-디클로로-1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸, 31. 4,5-디클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸, 32. 4,5-디클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸 염산염, 33. 4,5-디클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸 이염산염, 34. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕인돌, 35. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕인돌, 36. 4,5-디클로로-2-메틸-1-{4-〔4-(4-메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-이미다졸, 37. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 38. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-인다졸, 39. 2-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2H-인다졸, 40. 4-클로로-1-{4-〔4-(4-메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 41. 4-클로로-1-{4-〔4-(4-메톡시페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 42. 4-클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 43. 4,5-디클로로-1-{4-〔4-(4-메톡시페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸, 44. 2-페닐-1-{4-〔4-(4-메톡시페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-이미다졸, 45. 1-{4-〔4-(4-메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸, 46. R4, R5, R6 및 R7가 또다른 방향족 또는 비방향족 고리를 형성하지 않는 4,5-디페닐-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-이미다졸, 47. 4-클로로-1-{4-〔4-(1-나프틸)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 48. 4-클로로-1-{4-〔4-(2-나프틸)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 49. 1-{2-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸, 50. 1-{4-〔4-페닐〕-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸 염산염, 51. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸, 52. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸 염산염, 53. 4,5-디클로로-2-메틸-1-{4-〔4-(3-트리플루오로메틸페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈이미다졸 염산염, 54. 4-클로로-1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸 염산염, 55. 1-{4-〔4-(4-페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-인다졸 염산염, 56. 4,5-디클로로-1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-이미다졸 염산염, 57. 4-(4-클로로페닐)-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸 염산염, 58. 4-(4-클로로페닐)-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸, 59. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-트리아졸염산염, 60. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-트리아졸, 61. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2-메틸-1H-벤즈이미다졸, 62. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-인다졸, 63. 2-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2H-인다졸, 64. 2-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2H-벤즈트리아조 염산염, 65. 2-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-2H-벤즈트리아졸, 66. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈트리아졸 염산염, 67. 1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-벤즈트리아졸, 68. 4-클로로-1-{4-〔4-(4-플루오로페닐)-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸염산염, 69. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피라졸 염산염, 70. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-트리아졸 염산염, 71. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-이미다졸 염산염, 72. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피롤 염산염, 73. 1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-피롤, 74. 4-(4-클로로)-1-{4-〔4-히드록시-4-페닐-1-피페리디닐)부틸〕-1H-피라졸, 75. 1-{4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐)부틸〕-1H-피라졸, 76. 4-(4-클로로)-1-{4-〔4-히드록시-4-(3-트리플루오로메틸페닐)-1-피페리디닐)부틸〕-1H-피라졸, 77. 1-{4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐)부틸〕-1H-피라졸, 78. 2-{4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐)부틸〕-2H-인다졸, 79. 2-{4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐)부틸〕-2H-벤즈트리아졸, 80. 1-{4-〔4-(4-플루오로페닐)-4-히드록시-1-피페리디닐)부틸〕-2H-벤즈트리아졸, 81. 3-클로로-1-{4-〔4-페닐-1-피페리디닐)부틸〕-2H-벤즈트리아졸, 82. 3-클로로-1-{4-〔4-페닐-1-(1,2,3,6-테트라히드로피리디닐)부틸〕-1H-인다졸 염산염.
- 하기 반응중 하나 이상을 실시하여, 제1항 또는 제2항에 따른 일반식(I)의 화합물을 제조하는 방법; (1). 하기 일반식(II)의 스피란 유도체와 하기 일반식(III)의 질소함유 헤테로고리 화합물과의 반응;상기 식들에서, R1, R2, R3, A, Z1, Z2, Z3및 R6는 상기 정의와 동일하며, m은 0 내지 4의 범위를 갖는 값이며, X는 클로로, 브로모, 메실옥시 또는 토실옥시와 같은 이탈기를 의미한다. (2). 하기 일반식(Ⅳ)의 유도체, 하기 일반식(Ⅴ)의 알킬화제 및 일반식(Ⅲ)의 질소함유 헤테로고리 화합물 사이의 동시적인 "1회(one pot)"반응;상기 식들에서, R1, R2, R3, A, X, n, Z1, Z2, Z4및 R6는 상기 정의와 동일하다. (3). 알킬화 조건하에서 일반식(Ⅳ)의 아민과 하기 일반식(Ⅵ)의 유도체의 반응;상기 식들에서, R1, R2, R3, A, X, n, Z1, Z2, Z|4및 R6는 상기 정의와 동일하다. (4). 알킬화 조건하에서 일반식(Ⅶ)의 화합물과 일반식(Ⅲ)의 질소 함유 헤테로고리 화합물의 반응;상기 식들에서, R1, R2, R3, n, X, A, Z1, Z2, Z|4및 R6는 상기 정의와 동일하다. (5). 일반식(I)의 화합물의 탈수;상기 식들에서, R1, R2, R3, n, X, A, Z1, Z2, Z|4및 R6는 상기 정의와 동일하며, A는 히드록실기에 연결된 탄소 원자(C-OH)를 의미하며, 점선은 임의의 추가 결합이 없음을 의미한다. (6). 하기 일반식(Ⅷ)의 화합물에 페닐리튬 또는 페닐마그네슘 브로마이드 같은 유기금속 시약의 첨가;상기 식에서, n, Z1, Z2, Z4및 R6는 상기 정의와 동일하다. (7). 하기 일반식(Ⅸ) 화합물의 환원;상기 식에서, R1, R2, R3, A, n, Z1, Z2, Z4및 R6는 상기 정의와 동일하다.
- 제1항 또는 제2항에 있어서, 약제로서, 구체적으로 불안증, 정신병, 간질, 경련, 운동기능 장애, 건망증, 뇌혈관 질환 또는 노인성 치매의 치료 활성을 가진 약제로서의 용도를 가진 일반식(I)의 화합물 및 그 생리적 허용염.
- 약학적 허용 부형제 외에도, 제1항 또는 제2항에 따른 하나 이상의 일반식(I)의 화합물 또는 하나 이상의 그 생리적 허용염을 함유하는 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR94/09443 | 1994-07-29 | ||
FR9409443A FR2723091B1 (fr) | 1994-07-29 | 1994-07-29 | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
FR94/09,443 | 1994-07-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960704900A true KR960704900A (ko) | 1996-10-09 |
KR100389785B1 KR100389785B1 (ko) | 2003-10-04 |
Family
ID=9465902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960701606A KR100389785B1 (ko) | 1994-07-29 | 1995-07-26 | 시그마및/또는5에이취티1에이수용체에대한친화성을가진테트라히드로피리딘알킬아졸또는4-히드록시피페리딘알킬아졸 |
Country Status (22)
Country | Link |
---|---|
US (2) | US5731331A (ko) |
EP (1) | EP0721455B9 (ko) |
JP (2) | JP4035787B2 (ko) |
KR (1) | KR100389785B1 (ko) |
CN (1) | CN1120167C (ko) |
AT (1) | ATE229530T1 (ko) |
AU (1) | AU712479B2 (ko) |
BR (1) | BR9506292A (ko) |
CA (1) | CA2172986A1 (ko) |
CZ (1) | CZ293123B6 (ko) |
DE (1) | DE69529142T2 (ko) |
DK (1) | DK0721455T3 (ko) |
FI (1) | FI116386B (ko) |
FR (1) | FR2723091B1 (ko) |
HU (1) | HU220088B (ko) |
NO (1) | NO309379B1 (ko) |
NZ (1) | NZ291172A (ko) |
PL (1) | PL183766B1 (ko) |
PT (1) | PT721455E (ko) |
RU (1) | RU2168507C2 (ko) |
WO (1) | WO1996004287A1 (ko) |
ZA (1) | ZA956314B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2723091B1 (fr) * | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
FR2742052B1 (fr) * | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
GB9613423D0 (en) * | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
HUP9602763A3 (en) * | 1996-10-09 | 1999-05-28 | Egyt Gyogyszervegyeszeti Gyar | 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same |
US5919802A (en) * | 1997-12-05 | 1999-07-06 | Princeton University | Methods of preventing and/or treating temporal lobe epilepsy |
ES2151828B1 (es) * | 1998-07-10 | 2001-08-16 | Esteve Labor Dr | Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor. |
US6046331A (en) * | 1998-12-17 | 2000-04-04 | Synaptic Pharmaceutical Corporation | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
DE10109866A1 (de) * | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
DE10109867A1 (de) * | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
ES2251317B1 (es) * | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
WO2006021463A1 (en) * | 2004-08-27 | 2006-03-02 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
ES2251316B1 (es) * | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
KR100871077B1 (ko) * | 2007-05-11 | 2008-11-28 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
KR100895998B1 (ko) * | 2007-05-11 | 2009-05-07 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
KR100893394B1 (ko) * | 2007-05-11 | 2009-04-17 | 한국화학연구원 | 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물 |
US8198307B2 (en) * | 2007-05-11 | 2012-06-12 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
NZ600008A (en) | 2009-12-04 | 2014-10-31 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
MX2019000980A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
KR20190065246A (ko) | 2016-07-29 | 2019-06-11 | 선오비온 파마슈티컬스 인코포레이티드 | 화합물 및 조성물 및 이들의 용도 |
JP7146782B2 (ja) | 2017-02-16 | 2022-10-04 | サノビオン ファーマシューティカルズ インク | 統合失調症を処置する方法 |
CN109280030B (zh) * | 2017-07-19 | 2022-04-22 | 江苏恩华药业股份有限公司 | 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用 |
WO2019028165A1 (en) | 2017-08-02 | 2019-02-07 | Sunovion Pharmaceuticals Inc. | ISOCHROMAN COMPOUNDS AND USES THEREOF |
EA202091945A1 (ru) | 2018-02-16 | 2021-01-18 | Суновион Фармасьютикалз Инк. | Соли, кристаллические формы и способы их получения |
MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
EP4135690A1 (en) | 2020-04-14 | 2023-02-22 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3509153A (en) * | 1967-03-24 | 1970-04-28 | Miles Lab | 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles |
US3635982A (en) * | 1969-04-08 | 1972-01-18 | American Home Prod | Amino-substituted-quinoxalinyloxazolidines and -oxazines |
ES378315A1 (es) * | 1969-04-11 | 1972-06-01 | Robins Co Inc A H | Un procedimiento para la preparacion de 1 - (omega-susti- tuido-alcohil)-2-metilbenzimidazoles. |
JPS5011395B1 (ko) * | 1970-12-29 | 1975-04-30 | ||
NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
US3981881A (en) * | 1975-08-14 | 1976-09-21 | E. R. Squibb & Sons, Inc. | 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones |
US3994904A (en) * | 1976-03-08 | 1976-11-30 | Miles Laboratories, Inc. | 3-Substituted -5-phenyl-5-pyridyl hydantoins |
JPS5746983A (en) * | 1980-09-04 | 1982-03-17 | Eisai Co Ltd | Theophylline derivative and its preparation |
DE3307395A1 (de) * | 1982-03-02 | 1983-09-08 | Eisai Co., Ltd., Tokyo | Arzneimittel zur behandlung von schmerzen, fieber, gewebe- und/oder knochen- und gelenkentzuendungen mit einem gehalt an theobromin- oder theophyllinderivaten als aktivem bestandteil |
JPS58150511A (ja) * | 1982-03-02 | 1983-09-07 | Eisai Co Ltd | テオフイリン誘導体を有効成分とする脳循環代謝改善剤 |
US4539407A (en) * | 1983-12-13 | 1985-09-03 | American Home Products Corporation | β-Carboline anticonvulsants |
US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
US4754038A (en) * | 1987-02-26 | 1988-06-28 | American Home Products Corporation | Carboline histamine H1 antagonists |
US5296487A (en) * | 1990-01-02 | 1994-03-22 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
EP0436157B1 (en) * | 1990-01-02 | 1995-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
FR2672052B1 (fr) * | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
JP3198117B2 (ja) * | 1990-02-07 | 2001-08-13 | サントリー株式会社 | ピロロアゼピン誘導体 |
US5149817A (en) * | 1990-03-05 | 1992-09-22 | Shionogi & Co., Ltd. | Teirahydropyridine derivatives |
JPH04211059A (ja) * | 1990-03-05 | 1992-08-03 | Shionogi & Co Ltd | 新規なテトラヒドロピリジン誘導体 |
FR2671972B1 (fr) * | 1991-01-25 | 1995-03-03 | Esteve Labor Dr | Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives. |
FR2673628B1 (fr) * | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
JP3219281B2 (ja) * | 1991-04-03 | 2001-10-15 | 聰 竹尾 | 心筋保護剤 |
DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
JPH09505029A (ja) * | 1993-07-19 | 1997-05-20 | 藤沢薬品工業株式会社 | ドパミン受容体作動薬、5−HT受容体拮抗薬あるいはα▲下1▼受容体拮抗薬として有用なベンズイミダゾール誘導体 |
US5411960A (en) * | 1993-12-09 | 1995-05-02 | Bayer Aktiengesellschaft | Substituted pyrroloanthracenes and -diones |
FR2723091B1 (fr) * | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
-
1994
- 1994-07-29 FR FR9409443A patent/FR2723091B1/fr not_active Expired - Fee Related
-
1995
- 1995-06-07 US US08/473,066 patent/US5731331A/en not_active Expired - Lifetime
- 1995-07-26 CN CN95190813A patent/CN1120167C/zh not_active Expired - Fee Related
- 1995-07-26 PT PT95928478T patent/PT721455E/pt unknown
- 1995-07-26 PL PL95313716A patent/PL183766B1/pl not_active IP Right Cessation
- 1995-07-26 EP EP95928478A patent/EP0721455B9/fr not_active Expired - Lifetime
- 1995-07-26 NZ NZ291172A patent/NZ291172A/en unknown
- 1995-07-26 CA CA002172986A patent/CA2172986A1/fr not_active Abandoned
- 1995-07-26 JP JP50617496A patent/JP4035787B2/ja not_active Expired - Fee Related
- 1995-07-26 DE DE69529142T patent/DE69529142T2/de not_active Expired - Lifetime
- 1995-07-26 CZ CZ1996926A patent/CZ293123B6/cs not_active IP Right Cessation
- 1995-07-26 HU HU9600815A patent/HU220088B/hu not_active IP Right Cessation
- 1995-07-26 RU RU96110883/04A patent/RU2168507C2/ru not_active IP Right Cessation
- 1995-07-26 BR BR9506292A patent/BR9506292A/pt not_active IP Right Cessation
- 1995-07-26 DK DK95928478T patent/DK0721455T3/da active
- 1995-07-26 KR KR1019960701606A patent/KR100389785B1/ko not_active IP Right Cessation
- 1995-07-26 AU AU32225/95A patent/AU712479B2/en not_active Ceased
- 1995-07-26 AT AT95928478T patent/ATE229530T1/de not_active IP Right Cessation
- 1995-07-26 WO PCT/EP1995/002978 patent/WO1996004287A1/fr active IP Right Grant
- 1995-07-28 ZA ZA956314A patent/ZA956314B/xx unknown
-
1996
- 1996-03-25 NO NO961207A patent/NO309379B1/no unknown
- 1996-03-28 FI FI961412A patent/FI116386B/fi not_active IP Right Cessation
-
1998
- 1998-02-26 US US09/031,024 patent/US6232329B1/en not_active Expired - Fee Related
-
2006
- 2006-09-27 JP JP2006290515A patent/JP2007051154A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960704900A (ko) | 시그마 및/또는 5에이취티1에이 (5ht1a) 수용기에 대한 활성을 가진 테트라히드로피리딘-(또는 4-히드록시피레리딘) 알킬아졸 (tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors) | |
RU96110883A (ru) | Тетрагидропиридин-(или 4-гидроксипиперидин)-алкилазолы, обладающие активностью по отношению к рецепторам сигма- и/или 5нт1а-типа | |
US6265408B1 (en) | Sulphonamide derivatives and their use in the treatment of CNS disorders | |
RU2007134383A (ru) | Производные 1,5-диарилпиррола, их получение и применение в терапии | |
ZA200305626B (en) | Imidazole derivatives. | |
JPH05140151A (ja) | イミダゾール、トリアゾール及びテトラゾール誘導体 | |
EP0235752A2 (en) | Piperidine derivative, pharmaceutical composition containing the same and use | |
CZ277730B6 (en) | Pyridazine derivatives substituted by cyclic amines and process for preparing thereof | |
WO2005051917B1 (fr) | Derives de pyrazole a titre de medicaments pour le traitement des degenerescences neuronales aigues ou chroniques | |
AU2005322173A1 (en) | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders | |
IE42512B1 (en) | N-(4-piperidinyl)-n-phenylamides and-carbamates | |
RU2000129161A (ru) | Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт | |
US6020336A (en) | Indole and indazole compounds | |
US4082755A (en) | 1-[(Diarylmethyl)aminoalkyl]piperidimes | |
US5317025A (en) | Piperidinylthioindole derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as analgesics | |
RU97116580A (ru) | Триазоловое соединение и его фармакологически приемлемая соль и противогрибковая композиция | |
US4914204A (en) | 4-Pentafluorophenoxypiperidines | |
US4886794A (en) | 4-[(α,α-diaryl)-hydroxymethyl]-1-piperidinylalkyl-cyclic carbamate derivatives as allergic response inhibitors | |
RU2001103738A (ru) | Применение производных тетрагидропиридин (или 4-гидроксипиперидин) бутилазолов при получении лечебного средства для лечения боли | |
US5418242A (en) | Piperidinylthioindole derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as analgesics | |
AU747073B2 (en) | Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of medicament for the treatment of pain | |
US4954511A (en) | 4-pentafluorophenoxypiperidines | |
USRE34201E (en) | N-aryl-N-[4-(1-heterocyclicalkyl)piperidinyl]amides and pharmaceutical compositions and methods employing such compounds | |
CA2525849A1 (en) | 4-arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | |
US4933460A (en) | Piperdine substituted phenyl hydrazones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060609 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |